Dexrazoxane Injection, Powder, Lyophilized, For Solution
NDC Package 68083-195-01
Package Information
Dexrazoxane (dexrazoxane for injection) injection is dexrazoxane for injection is indicated for reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin dose of 300 mg/m2 and who will continue to receive doxorubicin therapy to maintain tumor control. This formulation utilizes a injection, powder, lyophilized, for solution delivery system. Marketed by Gland Pharma Limited, this product is identified by NDC 68083-195 and is authorized under FDA application ANDA207321.
Identification & Billing
- RxCUI: 1736585 - dexrazoxane 250 MG Injection
- RxCUI: 1736590 - dexrazoxane 500 MG Injection
- RxCUI: 1736590 - dexrazoxane (as dexrazoxane HCl) 500 MG Injection
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 68083 - Gland Pharma Limited
- 68083-195 - Dexrazoxane
- 68083-195-01 - 1 VIAL in 1 CARTON / 50 mL in 1 VIAL
- 68083-195 - Dexrazoxane
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 68083-195-01 identifies a specific commercial package of 1 vial in 1 carton / 50 ml in 1 vial of Dexrazoxane, a human prescription drug labeled by Gland Pharma Limited. This injection, powder, lyophilized, for solution is formulated for intravenous use and contains dexrazoxane hydrochloride as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Gland Pharma Limited on December 05, 2016. The current certification is valid through December 31, 2027.
How is this Gland Pharma Limited product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 68083019501. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.